Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer

BJU International

Volumn 98, Issue 1, 2006, Pages 50-53

  Chun, Felix K H ^a   Perrotte, Paul ^a   Briganti, Alberto ^a   Benayoun, Serge ^a   Lebeau, Thierry ^a   Ramirez, Alvaro ^a   Lewinshtein, Daniel J ^a   Valiquette, Luc ^a   Guay, Jean Pierre ^a   Karakiewicz, Pierre I ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Age specific PSA reference ranges; DRE; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADULT; AGED; AGING; CANADA; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK ASSESSMENT;

EID: 33745106706     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06193.x     Document Type: Article

References (15)

1. Canadian Cancer Society/ National Cancer Insitute of Canada. Canadian Cancer Statistics 2005. At http://www.ncic.cancer.ca. Accessed January 2006
2. Jemal A Tiwari RC Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004 54: 8 29
3. Mettlin CJ Murphy GP Ho R Menck HR. The National Cancer Database report on longitudinal observations on prostate cancer. Cancer 1996 77: 2162 6
4. Oesterling JE Jacobsen SJ Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993 270: 860 4
5. Thompson IM Pauler DK Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004 350: 2239 46.
6. Loeb S Roehl KA Antenor JAV Catalona WJ Suarez BK Nadler RB. Baseline PSA compared with median PSA for age group as predictor of pathologic tumor features in men <60 years of age. AUA Proceedings 2005, Abstract 533
7. Kundu SD Roehl KA Antenor JAV Catalona WJ Nadler RB. Age-Specific risk of prostate cancer if PSA is between the median value and commonly used biopsy thresholds. AUA 2005, Abstract 953
8. Catalona WJ Partin AW Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 279: 1542 7
9. Catalona WJ Smith DS Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 324: 1156 61.
10. Schroder FH van der Cruijsen-Koeter I de Koning HJ Vis AN Hoedemaeker RF Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000 163: 806 12
11. Lodding P Aus G Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50-66 years old with 3-4 ng./ml. Prostate specific antigen. J Urol 1998 159: 899 903
12. Christensson A Bjork T Nilsson O et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993 150: 100 5
13. Karakiewicz PI Benayoun S Kattan MW et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005 173: 1930 4
14. Oesterling JE Jacobsen SJ Klee GG et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995 154: 1090 5
15. Haese A Graefen M Huland H Lilja H. Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. Curr Urol Rep 2004 5: 231 40